logo
Recognizing and Managing the Symptoms of Narcolepsy

Recognizing and Managing the Symptoms of Narcolepsy

Health Line3 days ago
Key takeaways
Narcolepsy causes extreme daytime sleepiness, which can lead to dozing off at inappropriate times and difficulty concentrating.
Type 1 narcolepsy involves cataplexy, or sudden muscle weakness, that can be triggered by strong emotions, while both types can cause sleep paralysis and hallucinations as you fall asleep or wake up.
Lifestyle changes like short naps, regular sleep schedules, and avoiding caffeine, along with medications such as stimulants and SNRIs, can help manage narcolepsy symptoms.
Narcolepsy is a rare neurological condition that causes extreme daytime drowsiness and overwhelming urges to sleep.
Narcolepsy symptoms usually begin when people are in their teens. However, most diagnoses occur in people 20–40 years old.
There are two types of narcolepsy. Type 1 features a sudden loss of muscle tone, known as cataplexy. Type 2 does not have cataplexy as a symptom.
What causes narcolepsy is unknown, but people with type 1 usually have lower amounts of hypocretin, a brain protein that regulates sleep-wake cycles. This may be due to a gene mutation.
People with a parent or sibling with narcolepsy are up to 40 times more likely to have it.
Keep reading to learn more about narcolepsy symptoms and how to manage them.
Excessive daytime sleepiness
People with type 1 and type 2 narcolepsy experience excessive daytime sleepiness. You may doze off at inappropriate times during the day.
Because of this, you may lack energy and have difficulty concentrating.
Cataplexy
People with type 1 narcolepsy experience cataplexy. This sudden muscle weakness usually occurs in your face, neck, and knees.
Cataplexy can be mild, where your head drops, or it can be severe, causing you to collapse. It may look like you're having a seizure, but you're not.
Strong emotions like fear or anger, or when you're laughing, may trigger cataplexy.
The frequency of cataplexy varies by person. You may experience cataplexy several times a day or only once a year.
Medications such as sodium oxybate (Xyrem) and venlafaxine (Effexor) can help prevent cataplexy.
Sleep paralysis
Narcolepsy may cause you to lose muscle function while falling asleep or waking up. Sleep paralysis is the inability to move or talk during these times.
Episodes of sleep paralysis may last from a few seconds to a few minutes.
People who don't have narcolepsy may also experience sleep paralysis. According to the American Academy of Sleep Medicine, 5–40% of people experience it.
Hallucinations
As you fall asleep or wake up, you may hallucinate, seeing vivid images that aren't real. They may seem so realistic that they may scare you, and you may jump out of bed.
Most hallucinations are visual. They may also affect your other senses, such as touch, smell, and sound.
These visions that occur when you fall asleep are called hypnagogic hallucinations. About one-third of all people have these hallucinations at some point.
If you have narcolepsy, you may experience these hallucinations during the day.
Other symptoms
Some other symptoms associated with narcolepsy include:
Fragmented sleep: You may have difficulty falling asleep or staying asleep at night.
Automatic behaviors: If you fall asleep while eating, driving, or doing another activity, you may continue to do that activity without consciously knowing it.
Immediate rapid eye movement (REM) sleep: People usually begin the REM stage of sleep, during which dreaming occurs, about 60–90 minutes after falling asleep. With narcolepsy, you may enter REM sleep in under 15 minutes after falling asleep and at any time during the day.
How can I manage narcolepsy symptoms?
Although there is no cure for narcolepsy, you can manage its symptoms with lifestyle strategies and medications.
Some lifestyle strategies that may help include the following:
Take a few 15- to 20-minute naps during the day if possible.
Try to go to bed and wake up at the same times every day.
Let your teachers or supervisors know you have narcolepsy and may fall asleep.
Get regular physical activity during the week.
Avoid heavy meals, caffeine, and alcohol before bedtime.
Medications a doctor may prescribe to treat narcolepsy include:
stimulants to help reduce excessive daytime sleepiness, such as:
armodafinil (Nuvigil)
modafinil (Provigil)
methylphenidate (Ritalin)
serotonin-norepinephrine reuptake inhibitors (SNRIs) to hold off REM sleep and prevent symptoms like cataplexy and hallucinations, such as venlafaxine (Effexor)
pitolisant (Wakix), which reduces daytime sleepiness by releasing histamines in your brain
When to contact a doctor
If your daytime sleepiness affects your quality of life, or if you often fall asleep during the day, contact a doctor to determine the cause. They can make a diagnosis and prescribe treatments to help you feel better.
Takeaway
The symptoms of narcolepsy, especially excessive sleepiness, may make it difficult to do your daily activities.
A treatment plan that includes lifestyle strategies and medications can help you manage this condition and improve your quality of life.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

America's dairy farmers and ice cream producers agree to quit using artificial colors
America's dairy farmers and ice cream producers agree to quit using artificial colors

Fox News

time11 minutes ago

  • Fox News

America's dairy farmers and ice cream producers agree to quit using artificial colors

America's ice cream will be getting healthy again. U.S. Department of Agriculture Secretary Brook Rollins, together with U.S. Health and Human Services Secretary Robert F. Kennedy Jr. and U.S. Food and Drug Administration (FDA) Commissioner Dr. Mary Makary, made essentially this announcement on Monday. (See the video at the top of this article.) MAHA leaders, together with the International Dairy Foods Association (IDFA) and dairy farmers, announced that artificial colors in ice cream products will be eliminated by the end of 2027. Sec. Rollins told Fox News Digital in a statement, "Each one of these endeavors helps families make better choices and pursue healthier lives." "I appreciate IDFA members for spearheading this new initiative and finding ways to promote President Trump's Make America Healthy Again agenda," she added. Michael Dykes, IDFA CEO, said they've reduced sugar by 60% in America's schools and flavored milk, which is the No. 1 product for children. "This announcement today represents over 40 individual ice cream companies," said Dykes. "It's the single largest effort of its kind." Sec. Kennedy commended major food manufacturers that have pledged to take artificial coloring out of their foods. "With this addition today of the dairymen and the dairy food producers, we now have about 35% of the American food industry that has made commitments," said RFK Jr. He added the stats are in addition to about 35% to 40% of the food industry, which was "already organic and healthy and chemical-free." Dairy farmers from Michigan, Illinois, Idaho and Indiana were at the press conference. Schwoeppe Dairy farm owner and fifth-generation dairy farmer Sam Schwoeppe of Indiana touted the benefits of consuming whole milk. Her parents were foster parents, she said, and she personally witnessed the importance of good nutrition in her life, making it her core to her mission "to feed children." "I'll never forget one of my brothers arriving [at] our family at the age of nine with gray hair, bald patches on his head and skin flaking off his body due to a lack of nutrition," she said. "After one month of regular meals, including the dense nutrition provided by whole milk and dairy products — and of course, our regular weekend ice cream parties — he transformed into a little freckled-faced, red-headed boy," said Schwoeppe. "It is essential we consume good, wholesome food products," she added. "Products containing real dairy are the most nutritious options, and even though ice cream is decadent and has calories, it sure beats the heck out of candy and soda pop for a sweet treat." Dairy products are a good source of essential nutrients such as calcium, potassium and vitamin D, according to the 2020-2025 Dietary Guidelines. Commissioner Makary also announced the FDA will be approving another natural food dye: gardenia blue. "The sickness of American kids is not a willpower problem. It's not their fault. We can do things that will make the food supply healthier, one step at a time," said Makary. In May, the FDA approved three natural-source colors in food items: galdieria extract blue, butterfly pea flower extract and calcium phosphate. The MAHA movement has spread to a number of local communities — with Stella's Homemade Ice Cream in South Carolina, plus King Cone in Plover, Wisconsin, doing away with artificial food dyes, Fox News Digital previously reported.

Woman tragically died after choking on Nutella and toast
Woman tragically died after choking on Nutella and toast

Yahoo

time25 minutes ago

  • Yahoo

Woman tragically died after choking on Nutella and toast

A review into the circumstances surrounding the death of a woman who choked on Nutella and toast has found that a number of things could have been done better in terms of her care. Tina, from Birkenhead, was 61 when she died in hospital on November 20 2017. She had been taken there by ambulance the day before, only a day and a half after moving to an emergency care placement in Knowsley. Tina had been found unresponsive by a member of staff, who had left her alone briefly to get the phone while she was eating. Despite being placed on life support, she later died and her death was recorded as hypoxic brain injury, cardiac arrest, and choking on food. Tina was described as 'a sociable funny person' who was close to her sisters, liked listening to music, and eating chocolate. She was diagnosed with cerebral palsy as an infant, had difficulty with her speech, and as an adult had no teeth or dentures. READ MORE: Tribute to mum with 'kindest soul' found dead at home READ MORE: Couple 'scammed' by £170 airport parking fine after falling asleep She had a number of health issues including mobility and breathing problems, incontinence, and was classed as morbidly clinically obese. A report into her death said she 'had choking risks associated with eating too fast, not chewing sufficiently, and having too much food in her mouth at once.' Tina's case is one of two adult safeguarding reviews included in an annual update for Wirral councillors at an adult social care and public health committee meeting on July 15. Tina was initially cared for by her family but was later put into care under Wirral Council. The report said she did not like to be identified by her disability and did not like it if her support staff would discuss her weight or attempt to control her eating of chocolate. The review said she would throw herself on the floor or attempt to swallow batteries, latex gloves, and plastic items and could on occasion be 'verbally abusive and sometimes aggressive.' In November 2017, Tina had to move as her permanent accommodation was being upgraded. An emergency placement at a care home broke down and she became unhappy, prompting her to be moved three times on November 17. Following her death, it was deemed the circumstances around her death and the number of agencies involved meant 'there was reason to pursue further enquiries about potential organisational neglect that might have contributed to her early death.' On November 19, Tina asked for a roast dinner, dessert, and chocolate buttons as well as toast and Nutella. Notes said Tina was given 'lightly toasted bread cut into small pieces.' After Tina was found choking and needing emergency CPR, she was later taken to Whiston Hospital where she died at 5.30am on November 20. Tina's assessment said she needed supervision when eating to avoid any choking risk. A number of issues with the support provided was highlighted in the review and seven recommendations were made as a result. However some good areas of practice around communication, engagement with Tina and her family over her care, as well as support for community activities and the services involved were thanked for their willingness to improve. For the latest news and breaking news visit Get all the big headlines, pictures, analysis, opinion and video on the stories that matter to you. Follow us on Twitter @LivECHONews - the official Liverpool ECHO Twitter account - real news in real time. We're also on Facebook/theliverpoolecho - your must-see news, features, videos and pictures throughout the day from the Liverpool ECHO.

Topflight Pharma Development Veteran Joins Synendos
Topflight Pharma Development Veteran Joins Synendos

Yahoo

time33 minutes ago

  • Yahoo

Topflight Pharma Development Veteran Joins Synendos

Dr. George Garibaldi is named Chief Medical Officer (CMO) as Synendos transitions from Phase 1 into Phase 2 of its clinical development strategy Dr. George Garibaldi, MD BASEL, Switzerland, July 15, 2025 (GLOBE NEWSWIRE) -- Synendos Therapeutics ('Synendos'), the clinical-stage biotechnology company developing breakthrough therapies for neuropsychiatric disorders, announced today that it has named Dr. George Garibaldi, CMO. This appointment is particularly timely as the company moves towards Phase 2 clinical development of its lead drug asset SYT-510. Synendos CEO, Andrea Chicca said, "It's tremendous that Synendos can attract this calibre of talent and experience. George offers a nuanced clinical perspective on the urgent needs of the patients we are looking to help, combined with specific expertise in advancing transformative neuroscience therapies from concept to clinical adoption.' Dr. George Garibaldi is a psychiatrist and neuroscientist with more than 30 years of experience leading global clinical development programs in CNS disorders. His career spans leadership roles at Roche, Novartis and Janssen, where he oversaw the development of breakthrough treatments including Ocrevus® for primary progressive and relapsing remitting multiple sclerosis and Exelon® for Alzheimer's disease and Lewi body dementia. As co-founder of Noema Pharma, he spearheaded the in-licensing and advancement of shelved CNS assets, securing major venture funding and progressing them through pivotal clinical trials. Known for his strong beliefs in empowering patients, Dr. Garibaldi has published more than 100 peer-reviewed articles and has developed widely used clinician- and patient-reported outcome measures. He is a founder and past president of the International Society for CNS Clinical Trials and Methodology and is recognized by peers as a collaborative, strategic leader dedicated to advancing mental health and neuroscience therapeutics. 'Mental health and brain health have for far too long been underserved by traditional drug development models,' said Dr. Garibaldi. "Synendos is combining the pursuit of an innovative target with a commitment to rethinking how we design trials, measure outcomes and prioritize patient function. It's this willingness to be ahead of the curve with therapeutic innovation and a genuine patient focus that made me want to be part of the company.' He added, 'Society today recognizes that there is no health without mental health. We have the rare opportunity to chart our own path here. I am eager to lead this transformation and help this exceptional team advance the next generation of brain therapies that could truly change the lives of patients.' About SynendosSynendos is a clinical-stage, neuroscience company developing potentially breakthrough therapies for neuropsychiatric and other CNS disorders such as anxiety disorders, PTSD and other indications. We utilise the modulation of a new drug target in the endocannabinoid system (ECS) that enables restoration of the natural functioning of the brain. Synendos' lead drug candidate, SYT-510, belongs to a novel class of ECS modulators named Selective Endocannabinoid Re-uptake Inhibitors (SERIs). SERIs represent first-in-class, new chemical entities that modulate the ECS through a self-limiting mode of action (MoA) with the potential to deliver meaningful benefits to patients. This novel MoA has the potential to combine treatment of a range of symptoms with sustained efficacy in large patient populations together with the potential to address a key unmet need, that of chronic tolerability, allowing more patients to stay on treatment and regain an improved quality of life. For more information please contact: Synendos Therapeutics AG Simon Russell +41 79 138 5840 O Public Relations GmbHO'Patrick Wilson o@ 78 888 4332 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store